The NIAID mission and scope includes rapidly responding to infectious disease outbreaks and preparing for future pandemics through clinical product development, reagent production, and manufacturing. In following this mission, the VRC has prioritized development of vaccines and antibodies targeting Ebola that may lead to prevention and/or therapeutic treatment. Specifically, the VRC seeks to develop and manufacture Ebola bispecific antibody products.